title: New anticoagulants in atrial fibrillation management.
abstract: Three new oral anticoagulants have been evaluated in large registration trials and are now available in many jurisdictions for patients with atrial fibrillation. Questions arise whether these drugs are equally effective and safe for all patients. Now when we are moving away from decades with only one orally available drug for anticoagulation there is opportunity to tailor the therapy according to patient characteristics and preferences. This review addresses the interaction of various patient characteristics with the treatment and what features can assist the physician in the choice of anticoagulant for the individual patient.
authors: Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada. schulms@mcmaster.ca
authors: Sam
authors: S
authors: Schulman
mesh_terms: D000284:Administration, Oral; D000367:Age Factors; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology*; D001562:Benzimidazoles / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003374:Coumarins / Q000627:therapeutic use; D000069604:Dabigatran; D005260:Female; D006405:Hematology / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000139:chemically induced; D012737:Sex Factors; D014859:Warfarin / Q000627:therapeutic use; D015091:beta-Alanine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D003374:Coumarins; D010975:Platelet Aggregation Inhibitors; D011720:Pyrazoles; D011728:Pyridones; D015091:beta-Alanine; C522181:apixaban; D014859:Warfarin; C030123:coumarin; D000069604:Dabigatran